Resultado de búsqueda
17 de mar. de 2019 · Our trial, AUGUSTUS, confirms the safety and efficacy of apixaban, as compared with a vitamin K antagonist, at a dose recommended for patients with atrial fibrillation and shows that the effect...
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
3 de feb. de 2021 · Most recently, the AUGUSTUS (Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation) trial evaluated the independent effects of the oral anticoagulant apixaban and...
- Fatima Rodriguez, Robert A. Harrington
- 2021
15 de mar. de 2019 · Among patients with atrial fibrillation with recent ACS or PCI in the AUGUSTUS trial, adding apixaban to a P2Y 12 inhibitor resulted in lower bleeding compared with VKA with a lower rate of death or rehospitalization. In both arms, addition of aspirin resulted in greater bleeding without any difference in efficacy.
19 de ene. de 2021 · An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial.
- Ziad Hijazi, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger...
- 2021
18 de abr. de 2019 · ClinicalTrials.gov/NCT02415400. In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y<sub>12</sub> inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of isch ….
- R.D. Lopes, G. Heizer, R. Aronson, A.N. Vora, T. Massaro, R. Mehran, S.G. Goodman, S.G. Goodman, S. ...
- 2019
2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban ...
29 de mar. de 2020 · Using a 2×2 factorial study design, the AUGUSTUS trial confirmed the independent effect of apixaban, compared with VKA, and aspirin discontinuation in reducing bleeding. There were, however, numerically more ischemic events, including MI, stent thrombosis, and urgent revascularization, without aspirin.
